The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression

Niclosamide, a cell-permeable salicylanilide, was approved by the Food and Drug Administration for its anthelmintic efficiency. A growing body of evidence in recent years suggests that niclosamide exhibits potential tumor-suppressive activity. However, the role and molecular mechanism of niclosamide...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yangyang, Zhu, Hengyue, Xiao, Yanyi, Guo, Hangcheng, Lin, Miaomiao, Yuan, Ziwei, Yang, Xuejia, Huang, Youze, Zhang, Qiyu, Bai, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814035/
https://www.ncbi.nlm.nih.gov/pubmed/35115509
http://dx.doi.org/10.1038/s41419-022-04573-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814035/
https://www.ncbi.nlm.nih.gov/pubmed/35115509
http://dx.doi.org/10.1038/s41419-022-04573-7

Ejemplares similares